AneuFix可注射聚合物在EVAR术中填充动脉瘤囊的首次人体研究
本研究为首次人体单臂单中心可行性试验,纳入5例T2EL高危肾下腹主动脉瘤患者,在EVAR术中向瘤囊内注射AneuFix聚合物。技术成功率100%,无器械相关严重不良事件,12个月时瘤囊直径和体积均缩小,未观察到T2EL或再干预。
要点
- EVAR术中瘤囊填充AneuFix聚合物技术可行,技术成功率100%。
- 无器械相关严重不良事件,1例操作相关严重不良事件(失血1.5L)无后遗症。
- 12个月随访瘤囊直径和体积缩小,未发生T2EL或再干预。
核心结论
- 首次人体试验显示EVAR术中注射AneuFix聚合物填充瘤囊技术可行且安全,所有患者12个月时瘤囊缩小。
研究设计与样本
- 首次人体、单臂、单中心可行性试验(NCT04307992),纳入5例T2EL高危肾下腹主动脉瘤患者。
- 术中置入填充鞘,在支架移植物周围向瘤囊注射可注射聚合物。
- 主要结局为技术成功和安全性(操作或器械相关严重不良事件),次要结局包括AAA直径、体积、6和12个月T2EL、操作指标、再干预、破裂和死亡。
主要发现
- 4男1女,中位年龄68岁(范围63-82岁)。
- 技术成功100%(5/5),完全填充主动脉腔。
- 无器械相关严重不良事件;1例操作相关严重不良事件(经入路鞘失血1.5L)无临床后遗症。
- 中位聚合物体积50 mL(范围22-70 mL),注射时间7分钟(范围4-13分钟)。
- 中位AAA直径从术后62 mm降至6个月60 mm和12个月56 mm;体积从167 mL降至148 mL和127 mL;可评估随访期间无T2EL或再干预。
临床怎么用
- 对于T2EL高危的肾下AAA患者,EVAR术中可考虑使用AneuFix聚合物填充瘤囊以预防T2EL。
- 需注意操作相关失血风险,本试验中发生1例经入路鞘失血1.5L。
局限性
- 首次人体单臂单中心试验,样本量仅5例,可行性及安全性需多中心试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type II endoleak (T2EL) after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) can lead to aneurysm growth and rupture. Filling the aneurysm sac around the stent graft during EVAR may prevent T2EL. This study evaluated the feasibility and safety of a novel injectable polymer (AneuFix, TripleMed, Geleen, the Netherlands), for sac filling during EVAR in patients at high risk of T2EL. METHODS: This first in human, single arm, single centre feasibility trial (ClinicalTrials.gov identifier: NCT04307992) included five patients with infrarenal AAA at high risk of T2EL. During EVAR, a filling sheath was positioned within the aneurysm, and the sac was filled with injectable polymer around the stent graft. Primary outcomes were technical success and safety (serious adverse events (SAEs) related to the procedure or device). Secondary outcomes included AAA diameter, volume, T2EL presence at six and 12 months, procedural metrics, re-intervention, rupture, and death. Post-treatment evaluations were performed by a Data Safety and Monitoring Board after treatment of the second, fourth, and fifth patients. RESULTS: Four men and one woman (median age 68 years; range 63 - 82 years) were treated. Technical success was 100% (five of five), with complete aortic lumen filling. No device related SAEs occurred. One procedure related SAE (1.5 L blood loss via access sheath) resolved without clinical sequelae. Median polymer volume was 50 mL (range 22 - 70 mL) and injection time was seven minutes (range 4 - 13 minutes). The median AAA diameter decreased from 62 mm after procedure to 60 mm and 56 mm at six and 12 months, respectively. AAA volume decreased from 167 mL to 148 mL and 127 mL. No T2ELs or re-interventions occurred during follow up when assessable. CONCLUSION: In this first in human series, injectable polymer sac filling during EVAR appeared technically feasible and safe, with all patients showing sac shrinkage at 12 months. A multicentre feasibility and safety trial is in progress.
引用
- Smorenburg SPM, Lely RJ, Jongkind V, et al. First in Human Aortic Aneurysm Sac Filling with AneuFix Injectable Polymer during Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2025. PMID: 41475431. doi:10.1016/j.ejvs.2025.12.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。